Mitsubishi UFJ Trust & Banking’s CRISPR Therapeutics CRSP Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-31,433	Closed	-$1.48M	–	1055
2024 Q3	$1.48M	Sell	31,433 -1,777	-5%	-$90.2K	﹤0.01%	867
2024 Q2	$1.79M	Sell	33,210 -6,460	-16%	-$374K	﹤0.01%	803
2024 Q1	$2.7M	Sell	39,670 -2,490	-6%	-$178K	0.01%	754
2023 Q4	$2.64M	Sell	42,160 -6,360	-13%	-$352K	0.01%	754
2023 Q3	$2.2M	Buy	48,520 +19,230	+66%	+$993K	0.01%	776
2023 Q2	$1.64M	Sell	29,290 -1,680	-5%	-$95.3K	﹤0.01%	788
2023 Q1	$1.4M	Hold	30,970	–	–	﹤0.01%	795
2022 Q4	$1.26M	Hold	30,970	–	–	﹤0.01%	807
2022 Q3	$2.02M	Buy	+30,970	New	+$2.24M	0.01%	763

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's CRSP Position: Q4 2024 in Review

Mitsubishi UFJ Trust & Banking sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 31,433 shares — an estimated $1.48M sold.

Mitsubishi UFJ Trust & Banking first reported a position in CRSP in Q3 2022 and held it in 9 quarters. The position peaked at $2.7M in Q1 2024. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Mitsubishi UFJ Trust & Banking reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Mitsubishi UFJ Trust & Banking sold 31,433 CRISPR Therapeutics shares in Q4 2024, an estimated $1.48M.
Mitsubishi UFJ Trust & Banking first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 9 quarters.
Mitsubishi UFJ Trust & Banking's CRISPR Therapeutics position peaked at $2.7M in Q1 2024.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q4 2024, filed 12 Feb 2025.